| __timestamp | Insmed Incorporated | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 31073000 | 49315000 |
| Thursday, January 1, 2015 | 43216000 | 75043000 |
| Friday, January 1, 2016 | 50679000 | 83749000 |
| Sunday, January 1, 2017 | 79171000 | 122682000 |
| Monday, January 1, 2018 | 168218000 | 207761000 |
| Tuesday, January 1, 2019 | 210796000 | 284812000 |
| Wednesday, January 1, 2020 | 203613000 | 317875000 |
| Friday, January 1, 2021 | 234273000 | 282660000 |
| Saturday, January 1, 2022 | 265784000 | 451421000 |
| Sunday, January 1, 2023 | 344501000 | 481871000 |
Data in motion
In the competitive landscape of biotechnology, Insmed Incorporated and Sarepta Therapeutics, Inc. have been pivotal players. Over the past decade, their Selling, General, and Administrative (SG&A) expenses have shown significant growth, reflecting their strategic investments in operations and market expansion.
From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, starting from approximately $31 million to a staggering $345 million. Similarly, Sarepta's expenses increased by nearly 900%, from around $49 million to $482 million. This upward trend highlights the companies' commitment to scaling their operations and enhancing their market presence.
While both companies have shown robust growth, Sarepta consistently outpaced Insmed in SG&A spending, indicating a more aggressive expansion strategy. This financial trajectory underscores the dynamic nature of the biotech industry, where strategic spending is crucial for innovation and market leadership.
Eli Lilly and Company or Insmed Incorporated: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Sarepta Therapeutics, Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Insmed Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Sarepta Therapeutics, Inc.
Insmed Incorporated and Madrigal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Insmed Incorporated or Verona Pharma plc: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Insmed Incorporated or Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Verona Pharma plc
Sarepta Therapeutics, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Novavax, Inc.